Trial results for the Prostate Resection After Microwave Ablation (PRAMA) study in Prostate Cancer were posted on 2025-11-28, detailing findings from its single enrolled participant.
Background
Prostate cancer is a prevalent malignancy, ranking as the second most common cancer among men. While many prostate cancers are indolent and may never progress to an aggressive stage, a significant number of men opt for active treatment, often involving surgical intervention. Radical prostatectomy, the removal of the prostate gland and sometimes surrounding lymph nodes, is a common but invasive treatment. This procedure can lead to considerable negative impacts on a patient's quality of life. The PRAMA trial aimed to explore a less invasive approach by testing the safety and efficacy of targeted microwave ablation prior to radical prostatectomy.
Trial design
This completed study, identified as Phase NA, enrolled 1 participant with Prostate Carcinoma. The trial's objective was to test the safety of magnetic resonance imaging (MRI)/ultrasound (US) fusion guided transperineal targeted microwave ablation (TMA) before a radical prostatectomy (RP) and to assess its effectiveness in treating patients with prostate cancer.
What this means
The completion of this study, despite its limited enrollment of one participant, marks an initial step in evaluating the safety and efficacy of MRI/US fusion guided transperineal targeted microwave ablation prior to radical prostatectomy for prostate cancer. While no specific outcome data is available from the posted results, the study's completion indicates the feasibility of conducting such an investigation. Future research with larger cohorts would be necessary to draw definitive conclusions about this intervention's potential benefits for patients with prostate cancer.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT06128525, titled "Prostate Resection After Microwave Ablation (PRAMA)", were posted on 2025-11-28 on clinicaltrials.gov.